ZentraBio™ Retatrutide – 10 x 10 mg Vial

Description

 

Product Overview

ZentraBio™ Retatrutide is a precision-compounded formulation designed for advanced metabolic support and optimized body composition. Each sterile 10 mg vial contains lyophilized Retatrutide (triple-agonist peptide) requiring reconstitution with bacteriostatic (BA) water prior to subcutaneous use.
Formulated in GMP-compliant conditions, ZentraBio™ ensures pharmaceutical-grade purity and consistency for research and clinical applications under professional supervision.

---

Key Specifications

• Active Ingredient: Retatrutide 10 mg (per vial)
• Form: Lyophilized peptide powder
• Reconstitution: Add 1–2 mL bacteriostatic water before use
• Dosing Frequency: Typically administered once weekly or as directed by a qualified practitioner
• Mechanism of Action:
  Triple receptor agonist (GLP-1 / GIP / Glucagon) — enhances metabolic rate, suppresses appetite, and improves insulin and glucose regulation

---

Core Benefits

• Supports sustainable fat loss and improved metabolic health
• Promotes energy balance and increased caloric expenditure
• May aid in preserving lean muscle mass during weight reduction
• Encourages better appetite control and reduced cravings
• Enables flexible micro-dosing through controlled reconstitution

---

Usage & Preparation

1. Reconstitute vial contents with 1–2 mL bacteriostatic water using aseptic technique.
2. Gently swirl (do not shake) until fully dissolved.
3. Administer subcutaneously as guided by your healthcare professional.
4. Record date of reconstitution and discard any unused solution after 30 days.

ZentraBio™ Retatrutide is intended for clinical or research use only under medical supervision. Not a replacement for a balanced diet or active lifestyle.

---

Storage & Handling

• Store refrigerated at 2°C – 8°C
• Do not freeze
• Protect from light and prolonged heat exposure
• Once reconstituted, keep refrigerated and use within 30 days

---

Caution

Do not use if seal is broken or solution appears cloudy after reconstitution.
Not suitable for individuals with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). Always consult a healthcare professional before initiating peptide-based protocols.